Drugs in R & D最新文献

{"title":"A Case Report of JAK Inhibitors Therapy for Adult-Onset Still’s Disease with Persistent Pruritic Lesions","authors":"Li Tang, Hongjian Shi, Weijun Liu, Pingxiu He, Chun Huang, Xiaobing Wang","doi":"10.1007/s40268-024-00487-1","DOIUrl":"https://doi.org/10.1007/s40268-024-00487-1","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background and Objective</h3><p>Adult-onset Still’s disease (AOSD) is a recognized autoinflammatory disorder of unknown etiology. The standard initial management for AOSD includes conventional corticosteroids and disease-modifying antirheumatic drugs. In cases that are resistant to these treatments, additional therapeutic options such as immunosuppressants, biologics, and other alternative treatments may be considered. Yet, a significant proportion of patients remain unresponsive to these therapeutic interventions. Herein, a case is reported involving a patient with AOSD who had persistent pruritic lesions that did not respond to conventional therapy, but were alleviated with Janus kinase inhibitors (JAKi), namely baricitinib and upadacitinib. The objective is to expand the number of refractory AOSD cases treated with JAKi in clinical practice. Another aim is to offer potentially effective therapeutic options for AOSD patients who experience persistent pruritus.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A case was reported involving AOSD characterized by persistent pruritic lesions that failed to respond to conventional treatment, but showed favorable outcomes with JAKi therapy. An analysis of the PubMed literature was performed to assess the medication’s efficacy and explore possible mechanisms.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The present case study is one of the few documented instances exploring the use of JAKi for treating AOSD, aligning with previously published research. After initiating JAKi therapy, the patient exhibited significant improvement in symptoms, most notably a reduction in persistent pruritus. Additionally, there was a substantial decrease in the patient’s glucocorticoid dosage. Aside from minor renal function anomalies, no adverse reactions were observed.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>The present case illustrates that JAKi can provide rapid and sustained clinical improvement in patients with AOSD, especially those who have not responded to conventional treatment, and they have the ability to alleviate persistent itching. Further investigation is needed to ascertain the precise mechanism.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142257437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Early-Phase Clinical Trials in China During 2013–2022: A Review","authors":"Jianxiong Zhang, Peng Zhang, Haixue Wang, Ruihua Dong","doi":"10.1007/s40268-024-00489-z","DOIUrl":"https://doi.org/10.1007/s40268-024-00489-z","url":null,"abstract":"<p>Clinical trials on innovative drugs in China have witnessed a stage of rapid development in recent years. The introduction of a number of government policies has stimulated enthusiasm for research and development in the pharmaceutical industry. We analyzed the data of the early-phase clinical trials registered in the Chinese Center for Drug Evaluation (CDE) from September 6, 2013, to December 31, 2022. All related registration information disclosed on the CDE website, including posted time, drug classification, dosing formula, indications, trial design, and trial status, were summarized and analyzed. A total of 5336 early-phase clinical trials were identified. The quantity and growth rate of early-phase clinical trials have increased substantially each year. Chemical drugs accounted for the largest proportion of early-phase clinical trials, although it dropped from 85.7% in 2013 to 59.5% in 2022. Moreover, the number of oncology drugs has increased yearly, accounting for 49.2% of all early-phase clinical trials in 2022. We can conclude that during 2013–2022, the development of early-phase clinical trials has progressed due to government support and advanced development techniques. To enhance the efficiency and success rate of early-phase clinical trials in the future, it is necessary to acquire advanced technical support and improve standardized supervision systems.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142217323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Ornidazole Tablets Bioequivalence in Chinese Healthy Participants Under Fasted and Fed Conditions Using Pharmacokinetic Parameters","authors":"Yanrong Wang, Yuanyuan He, Weihong Li, Hongmin LI, Liyuan Tang, Xinya Dai, Yingzi Pei, Lijing Gao","doi":"10.1007/s40268-024-00457-7","DOIUrl":"https://doi.org/10.1007/s40268-024-00457-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background and Objective</h3><p>Ornidazole, the third generation of nitroimidazole derivatives after metronidazole and tinidazole, it exerts both bactericidal and antiprotozoal effects. The purpose of this study was to evaluate the pharmacokinetic and bioequivalence of two ornidazole tablets manufactured by two different manufacturers based on their pharmacokinetic parameters.</p><h3 data-test=\"abstract-sub-heading\">Patients and Methods</h3><p>Fasted and fed healthy Chinese volunteers participated in a randomized sequence, single-dose, open-label, two-period crossover trial. There were 24 participants in both the fed study and the fasted study. Following a 7-day washout period before receiving the alternative formulation, eligible research participants were randomly assigned (1:1) to receive a single dosage of either the reference formulation or the test formulation. Following tablet administration, plasma samples were obtained over 72 h and analyzed using liquid chromatography tandem mass spectrometry (LC–MS/MS) to evaluate ornidazole contents. maximum plasma concentration (<i>C</i>_max), time to <i>C</i>_max (<i>T</i>_max), the area under the curve (AUC) from <i>t</i> = 0 to infinity (AUC_0–∞), AUC from <i>t</i> = 0 to the last quantifiable concentration (AUC_0–<i>t</i>), half-life (<i>t</i>_1/2), and terminal elimination rate constant (<i>z</i>) were evaluated as pharmacokinetic (PK) parameters. The safety evaluation involved adverse events (AEs) incidence and alterations in laboratory tests (hepatic function, blood biochemistry, hematology, and urinalysis) or vital signs (temperature, pulse, and blood pressure).</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>For the bioequivalence assessment in the fast trial, the prime PK parameters comparison between the reference and test formulation revealed that the GMR (90% CI) values for AUC_0–<i>t</i>, <i>C</i>_max, and AUC_0–∞ were 100.97% (99.12–102.85%), 99.88% (90.63–110.08%), and 101.12% (99.17–103.11%), respectively. For the bioequivalence assessment in the fed trial, the key PK parameters comparison between the reference and test formulations revealed that the GMR (90% CI) values for AUC_0–<i>t</i>, <i>C</i>_max, and AUC_0–∞ were 103.00% (100.94–105.11%), 101.90% (99.63–104.22%), and 102.99% (100.87–105.16%), respectively. The geometric mean ratios (GMRs) for the primary pharmacokinetic parameters (<i>C</i>_max, AUC_0–72, and AUC_0–∞) between the two formulations and the corresponding 90% confidence intervals (CIs) were all within the range of 80.00–125.00% for both the fasting and fed states. Both treatments have comparable safety profiles.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The bioequivalence and tolerability of ornidazole tablet reference and test formulations were evaluated am","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140635541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation.","authors":"Ryohei Ono,&nbsp;Kazutaka Nishimura,&nbsp;Hidehisa Takahashi,&nbsp;Yasuhiko Hori,&nbsp;Kenichi Fukushima,&nbsp;Yoshio Kobayashi","doi":"10.1007/s40268-022-00403-5","DOIUrl":"https://doi.org/10.1007/s40268-022-00403-5","url":null,"abstract":"<p><strong>Background: </strong>Chromogenic anti-factor Xa activity (AXA) assay is used to measure the pharmacodynamics of factor Xa inhibitors, including edoxaban. Although AXA concentrations in patients with non-valvular atrial fibrillation using edoxaban have been reported, the impact of renal function on AXA concentrations with edoxaban use in patients with non-valvular atrial fibrillation has not been fully assessed.</p><p><strong>Methods: </strong>Trough and peak AXA concentrations were measured in 93 patients with non-valvular atrial fibrillation taking edoxaban (73.6 ± 11.2 years, 48 were male). The patients were divided into three groups: patients with moderate renal dysfunction (creatinine clearance 15-49 mL/min), mild renal dysfunction (creatinine clearance 50-95 mL/min), and normal renal function (creatinine clearance > 95 mL/min). Both trough and peak AXA concentrations were assessed among the groups according to the edoxaban dose (30 or 60 mg).</p><p><strong>Results: </strong>At a 30-mg dose, patients with moderate renal dysfunction showed significantly higher trough AXA concentrations than patients with mild renal dysfunction or normal renal function. At a 60-mg dose, patients with mild renal dysfunction showed significantly higher trough AXA concentrations than patients with normal renal function. Peak AXA concentrations were not significantly different between the groups. Creatinine clearance was significantly and negatively correlated with trough AXA concentrations at a 60-mg dose, whereas the correlation of creatinine clearance with AXA concentrations was borderline significant at a 30-mg dose. No correlation was found between creatinine clearance and peak AXA concentrations at either dose.</p><p><strong>Conclusions: </strong>Creatinine clearance tends to be negatively correlated with trough AXA concentrations in patients with non-valvular atrial fibrillation taking edoxaban, while renal function is not correlated with peak AXA concentrations.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"281-288"},"PeriodicalIF":3.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/b7/40268_2022_Article_403.PMC9700531.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40355444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics, Bioequivalence and Safety of Cloperastine in Chinese Healthy Subjects Under Fasting and Postprandial Conditions.","authors":"Hong-Yu Luo,&nbsp;Hui-Zhi Long,&nbsp;Zi-Wei Zhou,&nbsp;Shuo-Guo Xu,&nbsp;Feng-Jiao Li,&nbsp;Yan Cheng,&nbsp;Dan-Dan Wen,&nbsp;Ping Deng,&nbsp;Li-Chen Gao","doi":"10.1007/s40268-022-00406-2","DOIUrl":"https://doi.org/10.1007/s40268-022-00406-2","url":null,"abstract":"<p><strong>Background: </strong>Cloperastine is a pivotal antibechic widely prescribed to treat cough caused by respiratory diseases. The present trial evaluated the pharmacokinetics (PK), bioequivalence (BE) and safety effects of the generic test (T) tablet of cloperastine after single-dose administration of cloperastine, compared with the original reference (R) tablet of cloperastine.</p><p><strong>Objective: </strong>The purpose of this trial was to compare the PK, BE and safety of a test 10 mg versus the reference 10 mg formulation of cloperastine under fasting and postprandial conditions in healthy Chinese volunteers.</p><p><strong>Methods: </strong>A single-centre, randomised, open, double-cycle, self-crossover, single oral administration Phase I trial was performed in healthy Chinese volunteers. A total of 60 subjects were enrolled in either the fasting (28 subjects) or the postprandial condition (32 subjects). Subjects randomly received a single dose of the T or R preparation (10 mg dose). Plasma concentrations of cloperastine were analysed by a validated LC-MS/MS method. The primary endpoints of the PK parameters were the area under the plasma concentration-time curve from zero to 72 h (AUC_0-72h), under the plasma concentration-time curve from zero to infinity (AUC_0-∞) and the maximal plasma concentration (C_max). The equivalence standard range (80.0-125.0%) was used to evaluate the BE of the two preparations. The safety parameter as secondary endpoint was mainly evaluated by the occurrence of adverse events (AEs).</p><p><strong>Results: </strong>A total of 25 and 30 subjects in the fasting and postprandial conditions completed this clinical trial, respectively. The geometric mean ratio (GMR) of the T/R for the C_max, AUC_0-72h and AUC_0-∞ were 102.1%, 103.8% and 104.0% in the fasting condition, respectively. In the postprandial condition, the GMR of the T/R for the C_max, AUC_0-72h and AUC_0-∞ were 94.2%, 98.8% and 99.0%, respectively. All the values fell within the range (80.0-125.0%). The C_max and AUC_0-72h values of the T and R preparations in fasting and postprandial conditions were not statistically significant (P > 0.05). Furthermore, no serious adverse events (SAEs) occurred during the whole trial.</p><p><strong>Conclusions: </strong>The T and R preparations were bioequivalent under both conditions. Food has no significant effect on the absorption of cloperastine. Moreover, T and R preparations were well tolerated. The trial registration number (TRN) and date of registrations were CTR20212515, 13 October 2021.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"311-320"},"PeriodicalIF":3.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/ac/40268_2022_Article_406.PMC9651896.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40486073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese- and French-Manufactured Immediate-Release Glucophage^® Bioequivalence: A Randomized, Open-Label, Crossover Study.","authors":"Chaoying Hu,&nbsp;Dan Gao,&nbsp;Dandan Li,&nbsp;Dongli Zhou,&nbsp;Lan Zhang","doi":"10.1007/s40268-022-00405-3","DOIUrl":"https://doi.org/10.1007/s40268-022-00405-3","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to assess the bioequivalence, safety, and tolerability of Chinese- and French-manufactured Glucophage^® immediate-release (GIR) tablets under fasted and fed conditions in healthy volunteers. A bioequivalence study was proposed to support the manufacturing transfer.</p><p><strong>Methods: </strong>This was an open-label, randomized, two-period, two-sequence, crossover study. Subjects were randomly assigned to receive the test product (one 500 mg GIR tablet manufactured in China) or reference product (one 500 mg GIR tablet manufactured in France). The primary study endpoint was the area under the plasma concentration-time curve from time zero to the last sampling time (AUC_t) and maximum observed concentration (C_max).</p><p><strong>Results: </strong>In total, 96 subjects were screened and 44 subjects were randomly assigned to treatment (fasted group, 26 subjects; fed group, 18 subjects). All 44 subjects received the study drug, completed the study, and were included in the pharmacokinetic (PK) and safety analysis sets. Under fasted or fed conditions, the mean AUC_t and C_max (primary PK parameters) were comparable between the test and reference products. Point estimates for both parameters were close to 100% and the corresponding 90% confidence intervals were within the specified 80-125% bioequivalence boundary. There were no hypoglycemia-related adverse events (AEs) in either treatment group. All AEs in the present study were mild in severity.</p><p><strong>Conclusions: </strong>Bioequivalence between the test and reference GIR tablets was demonstrated under fasted and fed conditions and both were safe and well tolerated.</p><p><strong>Clinical trials registration: </strong>This study was registered at ClinicalTrials.gov under the identifying number NCT03393208.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"301-309"},"PeriodicalIF":3.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/ca/40268_2022_Article_405.PMC9700552.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40574857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study.","authors":"Maki Umemiya,&nbsp;Yoshihide Inayama,&nbsp;Eiji Nakatani,&nbsp;Kenta Ito,&nbsp;Mitsuru Tsuji,&nbsp;Teruki Yoshida,&nbsp;Sae Yu,&nbsp;Rei Gou,&nbsp;Naoki Horikawa,&nbsp;Hirohiko Tani,&nbsp;Kenzo Kosaka","doi":"10.1007/s40268-022-00399-y","DOIUrl":"https://doi.org/10.1007/s40268-022-00399-y","url":null,"abstract":"<p><strong>Background and objectives: </strong>Irinotecan sometimes causes lethal septic shock but the risk factors remain unclear. This retrospective case-control study explored the potential risk factors for septic shock following irinotecan treatment.</p><p><strong>Methods: </strong>All women who received irinotecan-containing chemotherapy for gynecologic malignancies at Shizuoka General Hospital from October 2014 to September 2020 were investigated. The clinical backgrounds and blood test results of those who developed septic shock after irinotecan-containing chemotherapy were compared with those who did not. Odds ratios (ORs) for developing septic shock after receiving irinotecan were calculated with 95% confidence intervals (CIs), using univariable logistic regression analysis.</p><p><strong>Results: </strong>During the study period, 147 women received irinotecan-containing chemotherapy. Three women developed septic shock due to neutropenic enterocolitis after irinotecan treatment, and 144 did not. The three patients with septic shock had recurrent cervical cancer, heterozygous variants in the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) gene (two patients had *1/*6, one had *1/*28 variants), a history of concurrent chemoradiation therapy, 50-60 Gy of pelvic irradiation, and platinum-combined chemotherapy. A history of pelvic irradiation was identified as a possible risk factor for developing septic shock after irinotecan-containing chemotherapy (OR 63.0, 95% CI 5.71-8635; p < 0.001). The OR of UGT1A1 polymorphism for septic shock was 9.09 (95% CI 0.86-1233; p = 0.070) in the complete case analysis.</p><p><strong>Conclusion: </strong>Medical personnel involved in cancer therapy should consider the possible risk of septic shock developing due to neutropenic enterocolitis when administering irinotecan-containing chemotherapy in patients with a history of pelvic irradiation.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"263-269"},"PeriodicalIF":3.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/47/40268_2022_Article_399.PMC9700533.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40627141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants.","authors":"Fumihiko Koiwa,&nbsp;Rie Yazawa,&nbsp;Masafumi Fukagawa,&nbsp;Daisuke Honda,&nbsp;Tadao Akizawa","doi":"10.1007/s40268-022-00385-4","DOIUrl":"https://doi.org/10.1007/s40268-022-00385-4","url":null,"abstract":"<p><strong>Background and objective: </strong>Upacicalcet sodium hydrate is a novel small-molecule calcimimetic and has potential as a therapeutic agent for secondary hyperparathyroidism. We assessed the pharmacokinetics, pharmacodynamics, safety, and tolerability of a single intravenous dose of upacicalcet in Japanese healthy adults.</p><p><strong>Method: </strong>This was a single-center, double-blinded, randomized, placebo-controlled, dose-escalation study. For each cohort, eight subjects were randomly assigned at a ratio of 3:1 to receive a single injection of placebo or upacicalcet 0.01, 0.1, 1.0, or 2.5 mg.</p><p><strong>Result: </strong>The plasma concentration of upacicalcet increased in a dose-dependent manner. Upacicalcet rapidly disappeared from plasma after administration. The half-life of upacicalcet was approximately 1-2 h. The major excretion route of upacicalcet was via urine. Serum intact parathyroid hormone decreased in accordance with the upacicalcet dose, from the lowest dose of 0.01 mg. Gastrointestinal disorders occurred in one patient in the 1.0 mg group and in five patients in the 2.5 mg group. All adverse events were nonserious, and no symptomatic hypocalcemia occurred.</p><p><strong>Conclusion: </strong>This study showed that upacicalcet acted as a calcimimetic and was excreted in the urine unchanged with little metabolism. Moreover, upacicalcet is a small molecule and has a small volume of distribution. In addition, less than 50% of upacicalcet binds to human plasma proteins. These findings suggest that upacicalcet administered to patients undergoing hemodialysis might be expected to have a long excretion period and sustained pharmacological effect.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"131-140"},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e1/02/40268_2022_Article_385.PMC9167405.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40330559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections.","authors":"Matthew W McCarthy","doi":"10.1007/s40268-022-00383-6","DOIUrl":"https://doi.org/10.1007/s40268-022-00383-6","url":null,"abstract":"<p><p>Lysins are bacteriophage-derived enzymes that degrade essential components of bacteria. Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, including Staphylococcus aureus, has a low resistance profile, eradicates biofilms, and acts synergistically with other antibiotics. Combinations including exebacase and standard of care antibiotics represent an alternative to antibiotic monotherapies currently used to treat invasive staphylococcal infections. This manuscript reviews what is known about exebacase and explores how this novel agent may be used in the future to treat human bacterial pathogens.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"113-117"},"PeriodicalIF":3.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/0a/40268_2022_Article_383.PMC9167414.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39931909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Talaporfin","authors":"","doi":"10.1007/s40278-022-08970-7","DOIUrl":"https://doi.org/10.1007/s40278-022-08970-7","url":null,"abstract":"","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":"74 1","pages":"69-71"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83186539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}